HC Wainwright & Co. Reiterates Buy on Dare Bioscience, Maintains $7 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Dare Bioscience (NASDAQ:DARE) and maintained a $7 price target.
May 22, 2023 | 10:08 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Douglas Tsao reiterates a Buy rating on Dare Bioscience and maintains a $7 price target.
The reiteration of a Buy rating and maintenance of a $7 price target by HC Wainwright & Co. analyst Douglas Tsao indicates a positive outlook for Dare Bioscience. This news is likely to have a positive impact on the stock price in the short term, as it shows continued confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100